These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

398 related articles for article (PubMed ID: 30839208)

  • 41. Discovery and Development of Cyclic Peptide Proteasome Stimulators.
    Nelson S; Harris TJ; Muli CS; Maresh ME; Baker B; Smith C; Neumann C; Trader DJ; Parkinson EI
    Chembiochem; 2024 Feb; 25(3):e202300671. PubMed ID: 38055197
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Proteomic analysis of protein homeostasis and aggregation.
    Laskowska E; Kuczyńska-Wiśnik D; Lipińska B
    J Proteomics; 2019 Apr; 198():98-112. PubMed ID: 30529741
    [TBL] [Abstract][Full Text] [Related]  

  • 43. 26S proteasomes become stably activated upon heat shock when ubiquitination and protein degradation increase.
    Lee D; Goldberg AL
    Proc Natl Acad Sci U S A; 2022 Jun; 119(25):e2122482119. PubMed ID: 35704754
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The ubiquitin-proteasome pathway in Parkinson's disease and other neurodegenerative diseases.
    Ross CA; Pickart CM
    Trends Cell Biol; 2004 Dec; 14(12):703-11. PubMed ID: 15564047
    [TBL] [Abstract][Full Text] [Related]  

  • 45. A common mechanism of proteasome impairment by neurodegenerative disease-associated oligomers.
    Thibaudeau TA; Anderson RT; Smith DM
    Nat Commun; 2018 Mar; 9(1):1097. PubMed ID: 29545515
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The ubiquitin-proteasome system in neurodegeneration.
    McKinnon C; Tabrizi SJ
    Antioxid Redox Signal; 2014 Dec; 21(17):2302-21. PubMed ID: 24437518
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Peptides that activate the 20S proteasome by gate opening increased oxidized protein removal and reduced protein aggregation.
    Dal Vechio FH; Cerqueira F; Augusto O; Lopes R; Demasi M
    Free Radic Biol Med; 2014 Feb; 67():304-13. PubMed ID: 24291399
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The nuclear proteasome and the degradation of oxidatively damaged proteins.
    Voss P; Grune T
    Amino Acids; 2007; 32(4):527-34. PubMed ID: 17103119
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Methods to Discover and Evaluate Proteasome Small Molecule Stimulators.
    Coleman RA; Trader DJ
    Molecules; 2019 Jun; 24(12):. PubMed ID: 31242677
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Development of inhibitors in the ubiquitination cascade.
    Zhang W; Sidhu SS
    FEBS Lett; 2014 Jan; 588(2):356-67. PubMed ID: 24239534
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Ubiquitin/proteasome pathway impairment in neurodegeneration: therapeutic implications.
    Huang Q; Figueiredo-Pereira ME
    Apoptosis; 2010 Nov; 15(11):1292-311. PubMed ID: 20131003
    [TBL] [Abstract][Full Text] [Related]  

  • 52. The Proteasome and Ageing.
    Hegde AN; Duke LM; Timm LE; Nobles H
    Subcell Biochem; 2023; 102():99-112. PubMed ID: 36600131
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Removing protein aggregates: the role of proteolysis in neurodegeneration.
    Nijholt DA; De Kimpe L; Elfrink HL; Hoozemans JJ; Scheper W
    Curr Med Chem; 2011; 18(16):2459-76. PubMed ID: 21568912
    [TBL] [Abstract][Full Text] [Related]  

  • 54. DNA damage and regulation of protein homeostasis.
    Paull TT
    DNA Repair (Amst); 2021 Sep; 105():103155. PubMed ID: 34116476
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Priming the Proteasome to Protect against Proteotoxicity.
    Wang X; Wang H
    Trends Mol Med; 2020 Jul; 26(7):639-648. PubMed ID: 32589934
    [TBL] [Abstract][Full Text] [Related]  

  • 56. A Tale of Two Tails: Efficient Profiling of Protein Degraders by Specific Functional and Target Engagement Readouts.
    Chernobrovkin AL; Cázares-Körner C; Friman T; Caballero IM; Amadio D; Martinez Molina D
    SLAS Discov; 2021 Apr; 26(4):534-546. PubMed ID: 33445986
    [TBL] [Abstract][Full Text] [Related]  

  • 57. A Practical Review of Proteasome Pharmacology.
    Thibaudeau TA; Smith DM
    Pharmacol Rev; 2019 Apr; 71(2):170-197. PubMed ID: 30867233
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Ubiquitin proteasome system as a pharmacological target in neurodegeneration.
    Hol EM; Fischer DF; Ovaa H; Scheper W
    Expert Rev Neurother; 2006 Sep; 6(9):1337-47. PubMed ID: 17009921
    [TBL] [Abstract][Full Text] [Related]  

  • 59. The role of protein clearance mechanisms in organismal ageing and age-related diseases.
    Vilchez D; Saez I; Dillin A
    Nat Commun; 2014 Dec; 5():5659. PubMed ID: 25482515
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Underlying mechanisms and chemical/biochemical therapeutic approaches to ameliorate protein misfolding neurodegenerative diseases.
    Hekmatimoghaddam S; Zare-Khormizi MR; Pourrajab F
    Biofactors; 2017 Nov; 43(6):737-759. PubMed ID: 26899445
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.